PODCAST:
April 21, 2026 ~ Chris Renwick and Lloyd Jackson spoke with Melissa Lavasani, CEO of Psychedelic Medicine Coalition. They discussed the executive order fast-tracking psychedelic research for mental health, and the need for new healthcare infrastructure.
WASHINGTON D.C. ~ President Donald Trump signed an executive order Monday to fast-track federal approvals to use certain psychedelic drugs in the treatment of mental health conditions.
He signed the order during a press conference at the Oval Office, which would direct the Department of Health and Human Services to allocate $50 million to states to allow the treatment of conditions like post-traumatic stress and depression with drugs like ibogaine and psilocybin. The order also directs the U.S. Food and Drug Administration to hasten medical reviews of these treatments.
Among the notable names at the press was the famous podcaster Joe Rogan, despite his recent directing criticisms towards the Trump administration over its handling of the Epstein files and the Iran War. However, he said he recently spoke to Trump, advocating for ibogaine. The president responded by saying, “Sounds great. Do you want FDA approval? Let’s do it.“
